Last reviewed 2026-04-20 · How we verify

ADI PEG

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Nausea
• Anemia
• Constipation
• Platelet Count Decreased
• Decreased Appetite
• Neutrophil Count Decreased
• White Blood Cell Decreased
• Lymphocyte Count Decreased
• Other
• Hypoalbuminemia
• Hypocalcemia

Key clinical trials

• Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (PHASE1, PHASE2)
• Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (PHASE1)
• Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) (PHASE1, PHASE2)
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers (PHASE1, PHASE2)
• Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia (PHASE1)
• Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma (PHASE3)
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer (PHASE2)
• Study of ADI-PEG 20 Versus Placebo in Subjects With NASH (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.